Authors
Kyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, Akitaka Makiyama, Toshihiro Kudo, Kentaro Yamazaki, Koushiro Ohtsubo, Taroh Satoh, Chigusa Morizane, Shogen Boku, Eiji Oki, Naoki Takahashi, Fumio Nagashima, Shigenori Kadowaki, Takeshi Kato, Yoshito Komatsu, Yohei Kubota, Akihito Tsuji, Yukiko Fukuda, Naoko Iida, Taro Shibuki, Hideaki Bando, Karam Ashouri, Sandra Algaze, Heinz-Josef Lenz, Takayuki Yoshino
Published in
Cancer science. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
AXL, a receptor tyrosine kinase, has been implicated in epithelial-mesenchymal transition, angiogenesis, immune evasion, and therapeutic resistance, but its relevance in upper gastrointestinal cancers remains incompletely defined. We analyzed 337 patients with advanced gastric (n = 287) or esophageal (n = 50) cancer enrolled in SCRUM-Japan MONSTAR-SCREEN-2, whose tumors were profiled by whole-exome and whole-transcriptome sequencing. Patients were classified as AXL-high (n = 169) or AXL-low (n = 168) using cancer type-specific median transcripts-per-million cutoffs. Median follow-up was 14.1 months. AXL-high tumors were associated with shorter overall survival than AXL-low tumors (median, 12.9 versus 17.1 months; hazard ratio, 1.58; 95% confidence interval, 1.17-2.14; p = 0.003), consistently in gastric (hazard ratio, 1.47; p = 0.020) and esophageal (hazard ratio, 2.46; p = 0.027) cancer. This association persisted after adjustment for cancer type, age, sex, number of metastatic sites, microsatellite instability status, and tumor mutational burden (hazard ratio, 1.59; 95% confidence interval, 1.14-2.22; p = 0.007). Among microsatellite stable patients treated with immune checkpoint blockade, AXL expression was not associated with progression-free survival (hazard ratio, 0.83; 95% confidence interval, 0.61-1.14; p = 0.255). AXL-high tumors showed stromal and vascular expansion, regulatory T-cell enrichment, higher expression of fibroblast growth factor receptor 1, vascular endothelial growth factor receptors 1-3, and MET, and enrichment of epithelial-mesenchymal transition, angiogenesis, and transforming growth factor beta signaling. High AXL expression identifies a poor-prognosis stromal-angiogenic phenotype in upper gastrointestinal cancers and warrants prospective validation as a prognostic, rather than predictive, biomarker. Trial Registration: UMIN Clinical Trials Registry, UMIN000043899.
PMID:
43012149
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0